Restless Legs Syndrome in Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-15

Study Completion Date

2018-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Restless legs syndrome (RLS) is defined as the spontaneous movement of the limbs (mainly legs) associated with unpleasant - painful sensation which is relieved by moving the affected limb. It is a common disorder in hemodialysis patients that leads to insomnia, impaired daytime functioning and quality of life. Symptoms of RLS are estimated to affect up to 25% of patients on dialysis when the international RLS diagnostic criteria are applied. Various pharmacological and non-pharmacological interventions have been used to treat primary RLS. However, the evidence for use of these interventions in people with End stage renal disease is not well established; and some have serious side effects. Because high oxidative stress has been implicated in the pathogenesis of RLS, investigators thought of evaluating the efficacy of vitamin C in reducing the severity of RLS symptoms in hemodialysis patients in this randomized, double-blind, placebo-controlled, two arm parallel trial. To note that only two studies were done worldwide that proved the efficacy of vitamin C in those patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)

NCT00942253

Restless Legs Syndrome End Stage Renal Disease Hemodialysis +2 more

COMPLETED PHASE2

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042

Restless Legs Syndrome End-Stage Renal Disease

COMPLETED PHASE3

Sleep Disturbance in Patients With End-Stage Renal Disease

NCT02583347

Renal Failure Chronic Requiring Hemodialysis Sleep Disorders

UNKNOWN

The Effects of Resveratrol on the Complications of Patients With Hemodialysis

NCT03352895

Chronic Kidney Disease

COMPLETED NA

Sleep Quality and Related Factors in Hemodialysis Patients

NCT01327560

Haemodialysis-induced Symptom

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators are proposing to carry out a clinical trial. Around 100 stable hemodialysis adult patients at Makassed general hospital dialysis center and around 150 patients at Sahel general hospital and Zahraa hospital will be assessed according to the international RLS criteria. The data on individual, clinical and laboratory indices will be obtained from patients' recorded files and interviews. The investigators will compare the RLS group versus the non RLS group according to these factors to find the independently associated factors for RLS in dialysis patients.

Those who fulfill all four diagnostic criteria for RLS (confirmed independently by 2 neurologists) will be classified as "RLS positive" and will be asked to answer 10 questions on the international RLS study group (IRLSSG) rating scale. The IRLSSG rating scale was also used to evaluate the severity of RLS symptoms. These patients will be randomly allocated to two parallel groups to receive vitamin C (200 mg) or placebo for eight weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Leg Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin C

RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.

Group Type EXPERIMENTAL

Vitamin C

Intervention Type OTHER

200 mg Vitamin C will be given on daily basis for 8 weeks

Placebo

RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

200 mg placebo will be given on daily basis for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C

200 mg Vitamin C will be given on daily basis for 8 weeks

Intervention Type OTHER

Placebo

200 mg placebo will be given on daily basis for 8 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients under regular hemodialysis
* with no acute illness
* not hospitalized

Exclusion Criteria

* Patients receiving:
* tricyclic antidepressants,
* selective serotonin reuptake inhibitors,
* dopamine antagonists,
* dopamine blocking,
* antiemetics,
* lithium,
* sedative antihistamines,
* Patients with a history of renal stones

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No